ClinConnect ClinConnect Logo
Search / Trial NCT01580215

Long Term Follow up Investigation of Endobronchial Valves in Emphysema

Launched by PULMONX INTERNATIONAL SÀRL · Apr 17, 2012

Trial Information

Current as of September 10, 2025

Terminated

Keywords

Valves Endobronchial Endoscopic Lung Volume Reduction Pulmonx Zephyr Chartis Emphysema Copd

ClinConnect Summary

Primary objective is pulmonary function as assessed by FEV1 and secondary objectives are health related quality of life as assessed by the modified MRC dyspnea score and by the COPD assessment test, and survival at five years. 2000 patients will be enrolled in the study from approximately 200 referring centres in Germany. Patients will be followed up at 3, 6, and 12 months, and then yearly up to 5 years. The study will observe normal clinical practice. No investigations beyond those performed in normal clinical practice will be required with the exception of two short questionnaires. Patien...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients of both genders of at least 18 years of age
  • Understand and voluntarily sign an informed consent form.
  • FEV1 \> 15% predicted and \< 45% predicted
  • RV \>180% predicted
  • Diagnosis of emphysema with CT evidence of hyperinflation . Absence of collateral ventilation according to Chartis Assessment System
  • Exclusion Criteria:
  • • Active pulmonary infection

About Pulmonx International Sàrl

Pulmonx International Sàrl is a leading medical technology company focused on advancing innovative solutions for patients with respiratory diseases, particularly those with chronic obstructive pulmonary disease (COPD) and other lung conditions. With a commitment to improving patient outcomes, Pulmonx develops and commercializes minimally invasive therapies, including its proprietary Zephyr® Endobronchial Valve system, designed to enhance lung function and quality of life. The company is dedicated to rigorous clinical research and collaboration with healthcare professionals, striving to push the boundaries of pulmonary care through cutting-edge technology and evidence-based practices.

Locations

Heidelberg, Germany

Patients applied

0 patients applied

Trial Officials

Felix JF Herth, Prof. Dr.

Principal Investigator

Medizinische Fakultät Heidelberg

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials